| Evotec SE (DE0005664809) | |||
7,25 EURStand (close): 01.07.25 |
 |
||
Nachrichten |
||
| Datum / Uhrzeit | Titel | Bewertung |
| 25.06.25 13:17:33 | Sector Update: Health Care Stocks Mixed Premarket Wednesday |  |
| Health care stocks were mixed premarket Wednesday, as the Health Care Select Sector SPDR Fund (XLV) PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in |
||
| 25.06.25 05:50:00 | Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury | |
| NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury ("AKI") patients, developed as part of a research consortium led by Kidney Research UK The study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chronic kidney disease ("CKD") transition and pediatric AKI. This partnership will enable Evotec to understand human disease progression on a molecular level and to perform targeted drug discovery in the field of AKI. HAMBURG, DE / ACCESS Newswire / June 25, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that it has joined the NURTuRE-AKI consortium for establishing a patient cohort for acute kidney injury (AKI), NURTuRE-AKI. This initiative will enable Evotec to identify key mechanisms that trigger AKI and to support the discovery of highly innovative treatments for AKI patients based on a molecular understanding of the disease. NURTuRE-AKI focuses on adult and pediatric cardiac surgery patients who are at high risk of developing AKI as well as patients undergoing AKI-to-CKD progression. The longitudinal study design includes biological sampling and clinical data collection at multiple time points for each patient. Blood, urine and research biopsy samples will be subjected to state-of-the-art omics analyses, forming the most comprehensive patient cohort for AKI and AKI-to-CKD worldwide. NURTuRE-AKI will be integral to Evotec's Molecular Patient Database (E.MPD), a repository of high-quality multi-omics data (PanOmics) and detailed clinical records. This new addition will further enhance Evotec's understanding of human diseases and expand its capabilities in precision medicine, drug discovery and development programs. "NURTuRE-AKI will unlock the identification of novel therapeutic targets and biomarkers based on comprehensive molecular and clinical patient data. This will accelerate the development of targeted therapies for a disease with a high unmet medical need, providing immense benefits for millions of patients worldwide", said Dr Cord Dohrmann, Chief Scientific Officer of Evotec . "We are extremely thrilled to be a vital part of this unique venture, which marks a significant step for Evotec in expanding its leadership in kidney disease drug discovery. To fully realize the potential of this initiative, we are actively seeking partners who share our commitment to transforming kidney disease treatment." Story Continues "Kidney Research UK are delighted to be partnering with Evotec and our other collaborators to develop NURTuRE-AKI, which will form a crucial resource for future research and innovation. We are already seeing important new findings from the initial NURTuRE CKD and INS cohorts and are confident that this venture has similarly great potential to change diagnosis and care for kidney disease patients." Elaine Davies, Director of research operation Kidney Research UK . About Acute Kidney Injury AKI is a sudden decline in kidney function, associated with an increased risk of mortality and a leading cause of chronic kidney disease (CKD). Major causes of AKI include alterations in blood pressure and the use of contrast agents for angiography, occurring during cardiac surgeries. Currently, there are no preventive or therapeutic treatments for AKI. About Kidney Research UK Kidney Research UK is the leading charity dedicated to funding research into the prevention, treatment and management of kidney disease. Led by the patient voice, we have spent over 60 years working with clinicians, scientists and partners across sectors to drive innovation and improve lives - investing £71 million in research over the last decade alone. Our vision is the day when everyone lives free from kidney disease. Find out more at www.kidneyresearchuk.org . About NURTuREand NURTuRE-AKI NURTuRE is a unique resource for the kidney disease community, accelerating discovery of new treatments and diagnostic approaches through secure provision of a rich resource of biological samples and data. The initial cohorts comprised 3,000 individuals with CKD and 740 with idiopathic nephrotic syndrome (INS). With the development of NURTuRE-AKI, this resource will be extended to include samples and data from AKI patients included in three sub cohorts. The first sub cohort comprises 400 adult individuals undergoing cardiac surgery with cardiopulmonary bypass. The risk of AKI incidence in this setting is approximately 30%, and there are currently 2 million open-heart surgeries per year worldwide. The second sub cohort will be formed by 150 pediatric cardiac surgery patients, and the third sub cohort 400 adult patients with persistent decline of renal failure indicating AKI to CKD progression. The study will run over a three-year period, the samples will be obtained through 13 NHS Trusts, with patients followed up at specific intervals. In addition to the samples of plasma, serum, urine, DNA and tissue, NURTuRE-AKIwill also have the considerable advantage of containing associated linked clinical data, through the UK Renal Registry. NURTuRE-AKI is funded by Evotec, AstraZeneca, Nephrolyx and Kidney Research UK. Experts from the Leeds Teaching Hospital NHS Trust, University of Bristol and University Hospital Birmingham form the core academic team overseeing all operational delivery. More information is available here: www.nurturebiobank.org . About Evotec SE Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn . Forward-looking statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. For further information, please contact: Media Susanne Kreuter VP Head of Strategic Marketing Susanne.Kreuter@evotec.com Investor Relations Volker Braun EVP Head of Global Investor Relations & ESG Volker.Braun@evotec.com SOURCE: Evotec SE View the original press release on ACCESS Newswire View Comments |
||
| 07.05.25 07:06:22 | Evotec SE (EVO) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and Embracing ... | |
| Group Revenue: EUR200 million, a 4% decrease versus Q1 2024. Shared R&D Revenue: EUR140.6 million, down from EUR155.2 million in Q1 2024. Just Evotec Biologics Revenue: EUR59.4 million, showing strong growth. Adjusted Group EBITDA: EUR3.1 million. Operating Cash Flow: Improved versus prior year due to favorable changes in working capital. CapEx Spending: EUR18 million in Q1 2025, a reduction from Q1 2024. Liquidity: Decreased by EUR26 million to EUR371 million by end of March 2025. Net Debt: Increased to EUR107 million, with a net debt leverage of 5.97 times adjusted. Full Year 2025 Guidance: Group revenues of EUR840 million to EUR880 million, R&D expenditure of EUR40 million to EUR50 million, and adjusted EBITDA of EUR30 million to EUR50 million. Warning! GuruFocus has detected 4 Warning Signs with EVO. Release Date: May 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Evotec SE (NASDAQ:EVO) has made significant progress in its protein degradation collaboration with BMS, showcasing its strategy of technology leadership. The company received a grant from the Korean government to develop novel antibody treatments for lung fibrosis, highlighting its capabilities in drug discovery. Just Evotec Biologics delivered strong growth in Q1 2025, with revenues slightly ahead of expectations. Evotec SE (NASDAQ:EVO) is leveraging cutting-edge technology and AI-driven innovation to accelerate drug discovery and improve success probabilities. The company has implemented significant cost-saving measures, including site closures and headcount reductions, which are expected to positively impact future financials. Negative Points Evotec SE (NASDAQ:EVO) experienced a 4% decrease in group revenues in Q1 2025 compared to Q1 2024, primarily due to a decline in shared R&D revenue. The market for shared R&D remains soft, resulting in revenue decline and performance slightly below expectations. The company faces temporary lower BMS revenue, which is expected to continue in the midterm. Evotec SE (NASDAQ:EVO) has a temporarily elevated net debt leverage, with a net debt of EUR107 million. The company is operating in a cautious market environment with conservative spending from clients, impacting revenue growth. Q & A Highlights Q: Given the deviation in segment performance, with shared R&D underperforming and Just Evotec Biologics (JEB) overperforming, do you expect this trend to persist? Also, how might biotech and pharma layoffs impact your CRO activities? A: (Christian Wojczewski Wojczewski, CEO) The guidance remains unchanged as the overall revenue is balanced by the performance of both segments. The shared R&D market remains soft, but we are confident in our guidance. Layoffs in biotech and pharma could lead to more CRO activities as companies outsource work. Story Continues Q: Can you provide details on your pipeline for Just Evotec Biologics and shared R&D, particularly regarding customer and product concentration? Also, what are the details of your covenant waiver and working capital improvements? A: (Christian Wojczewski Wojczewski, CEO & Paul Hitchin, CFO) Customer concentration peaked in 2023-2024 but has since softened. We have a covenant waiver until Q3 2025, with testing in Q4. Working capital improvements are expected from BMS payments and Just-related work orders. Q: What gives you confidence in a recovery for shared R&D in the second half of the year? How do future BMS work packages factor into this? A: (Christian Wojczewski Wojczewski, CEO) Conversations with clients remain positive, though spending is cautious. BMS work packages are part of a large, multi-year program with varying revenue profiles, contributing to long-term growth. Q: Regarding Just Evotec Biologics, how will the ramp-up costs for Toulouse be phased over the year? A: (Paul Hitchin, CFO) The first quarter was stronger than expected, and ramp-up costs will continue throughout the year to support future growth. Q: How might potential cuts to NIH funding in the US impact Evotec, and could this create opportunities for you? A: (Christian Wojczewski Wojczewski, CEO) Our exposure to NIH is limited, so direct impact is minimal. We are prepared to serve clients in the US with our facilities, but the situation remains dynamic. Q: With the FDA's intention to phase out animal testing for biologics, how is Evotec positioned to adapt to these changes? A: (Paul Hitchin, CFO) Evotec is well-positioned with patient-centric approaches, iPSC technology, and PanOmics. The FDA's announcement is welcome, and we expect increased traction in discussions about these technologies. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments |
||
| 18.04.25 07:01:31 | Evotec SE (EVO) (Q4 2024) Earnings Call Highlights: Strong Q4 Performance and Strategic ... | |
| Group Revenue: EUR797 million, a 2% increase versus 2023. Shared R&D Revenue: Declined from EUR673 million in 2023 to EUR611 million in 2024. Just - Evotec Biologics Revenue: EUR185.6 million in 2024, up from EUR108.4 million in 2023, a growth of 71%. R&D Spending: Reduced by 26% from EUR68.5 million in 2023 to EUR50.9 million in 2024. Adjusted EBITDA: EUR22.6 million for 2024. Q4 Revenue: EUR221.2 million, a 20% increase versus the third quarter. Q4 Gross Margin: Improved to 20.8%. Q4 Adjusted EBITDA: EUR28.5 million, a EUR33 million uplift versus the prior quarter. Operating Cash Flow: EUR74.2 million in the fourth quarter. Total Liquidity: Increased by EUR94 million versus third quarter, leading to a year-end balance of EUR397 million. Net Debt: Improved to EUR43 million with a net debt leverage of 1.9 times. Priority Reset Savings: EUR40 million of run rate savings to be fully P&L visible in 2025. Headcount Reduction: Approximately 280 completed role reductions by the end of 2024. Warning! GuruFocus has detected 5 Warning Signs with EVO. Release Date: April 17, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Evotec SE (NASDAQ:EVO) reported strong Q4 2024 results, marking the second-best quarter ever in terms of revenue, with significant operational leverage. The company successfully strengthened partnerships with major players like Sandoz, Bristol Myers Squibb, Novo Nordisk, Pfizer, and Bayer, paving the way for long-term growth. Just - Evotec Biologics saw a 71% revenue growth in 2024, driven by a strong order book and new deals. Evotec SE (NASDAQ:EVO) implemented a priority reset, achieving EUR40 million in run rate savings, which will be fully visible in 2025. The company is focusing on technology and science leadership, leveraging AI and next-generation technologies to enhance drug discovery and development processes. Negative Points Shared R&D revenue declined from EUR673 million in 2023 to EUR611 million in 2024 due to a persisting soft market. The company faced a challenging year with a high fixed cost base and slow market demand for its R&D segment. Evotec SE (NASDAQ:EVO) anticipates continued softness in the biopharma market throughout 2025, with a potential tipping point for growth not expected until the second half of the year. The company is not planning to invest in a new J.POD facility during the current planning horizon, indicating a cautious approach to capital expenditure. There are concerns about the indirect impact of potential budget cuts in the US on innovation and the biotech industry, which could affect future growth. Story Continues Q & A Highlights Q: What is the sustainable level of income tax credits or R&D tax credits for Evotec, and are there any risks to these credits? A: Paul Hitchin, CFO, stated that the tax credits are expected to grow in line with business growth and where R&D work is performed. Currently, there are no perceived risks to these credits. Q: Can you provide more details about the composition of Evotec's drug portfolio, specifically the phase composition of the 100 products? A: Cord Dohrmann, Chief Scientific Officer, explained that there are six assets in clinical stages and six in preclinical stages. Over the next 24 months, about 15 assets have the potential to move from preclinical to clinical stages. Q: How sophisticated are the models for phasing out animal testing, and is it possible to eliminate animal testing in the foreseeable future? A: Cord Dohrmann noted that Evotec is well-positioned to support the FDA's initiative to phase out animal testing. The company has developed advanced human microphysiological systems and AI-based approaches, which are expected to significantly improve predictive accuracy. Q: What are the growth drivers for Just - Evotec Biologics over the next 12 to 18 months, and how de-risked are these drivers? A: Christian Wojczewski, CEO, mentioned that there is high confidence in the growth of Just - Evotec Biologics due to pre-commitments from partners like Sandoz and a strong customer base developed over the last two years. Q: What is the synergy between Evotec's divisions, and what was the rationale for owning these businesses? A: Christian Wojczewski explained that the synergy lies in technology and science leadership, enabling partners to succeed. Shared R&D focuses on small molecules, while Just - Evotec Biologics focuses on large molecules, both leveraging technology to enhance partner success. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments |
||
| 17.04.25 05:45:00 | Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results | |
| Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth Strategy builds on technology and science leadership, focusing on high-growth, high-value segments, simplifying the business model and fostering operational excellence Strong Q4 2024 revenue and EBITDA results in spite of challenging market conditions. Full year guidance met, with liquidity significantly improved Priority Reset on track to deliver annualised recurring gross savings of € 40 m 2025 guidance: group revenues to grow 5 - 10 % (€ 840 - 880 m); 2028 outlook foresees revenue CAGR2024-2028 between 8 - 12% and generation of EBITDA margin above 20 % HAMBURG, GERMANY / ACCESS Newswire / April 17, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN:DE0005664809; NASDAQ:EVO) today announced its financial results for FY 2024, provided guidance for FY 2025 and outlook for 2028 reflecting the path to sustainable profitable growth, following the completion of its strategic review process. Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: "Evotec's ambitious new direction paves the way for sustainable profitable long-term growth. We are refocusing Evotec on its core strengths: technology and science leadership, where we deliver maximum impact for customers and patients. By combining cutting-edge technology platforms, disruptive science, and AI-driven innovation, we are accelerating the journey from concept to cure with our partners. We delivered on 2024 financial guidance, and I am excited about the opportunities that lie ahead of us. Together with our talented teams, we are writing the next chapter of Evotec's success story as a drug discovery pioneer." Evotec unveils new strategy to refocus on core strengths and define clear roadmap to sustainable profitable growth Technology and science leadership - refocusing on our strong, unique heritage Two pillars: Drug Discovery & Pre-clinical Development (Shared R&D) and Just - Evotec Biologics Drug Discovery & Pre-clinical Development will leverage automation, industrialisation, next generation platforms and AI to accelerate our customers journey and to increase their success rates Business model simplified: focus on high-value services and therapeutic areas, asset portfolio streamlined by ~30 %, R&D supporting next-generation technology development. Exiting equity participations Just - Evotec Biologics growth underpinned by existing partnerships and further strengthened by leveraging its capabilities as a scalable technology and service provider, anticipating pivot to an asset lighter model Beating market growth via our scientific and operational expertise, focus, and differentiated technology Commitment to operational excellence for a step-change in performance. Driving operational leverage through our backbone with higher focus on automation. Anchored cost-out initiatives via refined footprint, optimised COGS and SG&A delivering > € 50 m gross savings by 2028 on top of Priority Reset (€ 40 m) Story Continues 2024 revenue and EBITDA within guidance. Priority Reset on track. Q4: Second highest quarterly revenues ever amid challenging market environment Group revenues increased by 2 % to € 797.0 m (2023: € 781.4 m); Q4 2024 revenues increased by 10 % to € 221.2 m from € 201.3 m in Q4 2023 Evotec's Just - Evotec Biologics segment saw impressive growth, with revenues rising by 71 % year-over-year, contributing € 185.6 m (2023: € 108.4 m) to the overall topline Total Shared R&D revenues decreased by 9 % to € 611.4 m (2023: € 673.0 m); Demand still affected by temporary Pharma restructuring and selective funding for Biotech Adjusted Group EBITDA totalled € 22.6 m (2023: € 66.4 m) driven by a mismatch between revenues and cost base in the Shared R&D segment Priority Reset on track to secure an annualised adjusted EBITDA improvement of over € 40 m. One-off costs recognised at € 54.9 m, vs. initial provision of € 68.5 m Net debt leverage ratio significantly improved to 1.9x net debt / EBITDA Strengthened partnerships in 2024 paving the way for 2025 growth in soft market environment Group revenue growth expected to accelerate vs. 2024, driven by Just - Evotec Biologics, while Shared R&D revenues expected to remain around 2024 levels Tariffs & US government funding development are expected to have a limited impact on Evotec's business Expansion of technology partnership with Sandoz and new customers for long-term development and commercial manufacturing in Biologics Progress and extension of multi-year collaboration with Bristol Myers Squibb ("BMS") in neuroscience and targeted protein degradation New technology development partnership with Novo Nordisk to support next-generation cell therapies New multi-year master research collaboration with Pfizer, initially focusing on early discovery research for metabolic and infectious diseases Guidance for full-year 2025 Group revenues expected in the range of € 840 - 880 m (2024: € 797.0 m) R&D expenditures are expected in a range of € 40 - 50 m (2024: € 50.8 m) Adjusted Group EBITDA is expected to reach € 30 - 50 m (2024: € 22.6 m) Outlook 2028 Group revenues CAGR 2024-2028 targeted to be in a range of 8 - 12 % Adj. EBITDA margin 2028 expected to be above 20 % CAGR: Compound annual growth rate More detailed information and financial tables are available in the annual report published on the Evotec website under the following link: https://www.evotec.com/en/investor-relations/financial-publications Webcast/Conference Call The Company plans to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English. Webcast details Date: Thursday, 17 April 2025 Time: 2.00 pm CEST (01.00 pm BST, 08.00 am EDT) To join the audio webcast and to access the presentation slides, please register via this link. The on-demand version of the webcast will be available on our website: www.evotec.com/en/investor-relations/financial-publications. Conference call details To join via phone, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call. A simultaneous slide presentation for participants dialling in via phone is available under this link. About Evotec SE Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 100 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,800 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn. Forward-looking-statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. For further information, please contact: Investor Relations Volker Braun EVP Head of Global Investor Relations & ESG volker.braun@evotec.com SOURCE: Evotec SE View the original press release on ACCESS Newswire View Comments |
||
| 10.04.25 10:00:00 | Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025 | |
| HAMBURG, DE / ACCESS Newswire / April 10, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 April 2025. The Company is going to host a conference call to discuss 2024 results as well as to provide an update on the concluded strategic review process. The conference call will be held in English. Webcast details Date: Thursday, 17 April 2025 Time: 2.00 pm CEST (1.00 pm BST, 8.00 am ET) To join the audio webcast and to access the presentation slides, please register via this link. The on-demand version of the webcast will be available on our website: www.evotec.com. Conference call details To join via phone, please pre-register via this link . You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call. A simultaneous slide presentation for participants dialing in via phone is available under this link . About Evotec SE Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 100 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,800 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn . Forward-looking statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Story Continues For further information, please contact: Investor Relations Volker Braun EVP Head of Global Investor Relations & ESG Volker.Braun@evotec.com SOURCE: Evotec SE View the original press release on ACCESS Newswire View Comments |
||
| 02.04.25 19:30:35 | Is Evotec (EVO) the Best German Stock to Buy According to Hedge Funds? | |
| We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Evotec (NASDAQ:EVO) stands against other best German stocks to buy according to hedge funds. Germany’s economy is facing continued weakness. According to a report published by Roland Berger, the 0.1% contraction in 2023 and the 0.2% in 2o24 will only be countered by a 0.4% projected growth in 2025. While manufacturing orders are recovering modestly since June last year, business sentiments are still low and the industrial production for November was down 3,1% year-over-year. Unemployment also reached 2.81 million in December 2024, which was a 170,000 increase as compared to the same period last year. This pushed the unemployment rate to 6%. Inflation is now expected to average 2% in 2025, which is still down from the 2.2% figure from 2024. Earlier on March 6, Chris Verrone, Strategas, joined CNBC’s ‘Fast Money’ to express his bullish outlook on the European market. He highlighted a shift in global cyclicality eastward and observed that the European industrials are achieving new highs. Verrone emphasized that the European banks have shown strength over the past 18 months but despite such trends, investors are still not heavily leaning towards European equities. He cited the German ETF under the name of EWG to support his stance, as EWG broke a 20-year high which indicated its departure from prolonged secular stagnation particularly within banks and industrials. However, he did note that energy and basic resources are not showing the same momentum. The conversation also covered the fact that investors have been overweight in US large-cap tech stocks over the past 12 to 13 years. Verrone relayed that observed extreme bearishness towards the European market as of December 2024, when he visited the region. He particularly noted that peripheral European markets, which include countries like Italy and Spain, have been leading. Whereas Germany has lagged. While Verrone mentioned that he heard Christine Lagarde, President of the European Central Bank, expressed pessimism about the European economy herself during the world economic forum in Davos, he still maintains his bullish outlook. He thinks that the European economic data is improving and global cyclicality has not been extinguished. Our Methodology We used the Finviz stock screener to compile an initial list of top German stocks. We then selected 12 German stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2024. The hedge fund data was sourced from Insider Monkey’s database which tracks the moves of over 900 elite money managers. Story Continues Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).Is Evotec (EVO) the Best German Stock to Buy According to Hedge Funds? A technician recording data from a complex experiment involving pharmaceutical products. Evotec (NASDAQ:EVO) Number of Hedge Fund Holders: 1 Evotec (NASDAQ:EVO) is a drug discovery and development company that partners with pharmaceutical and biotech firms to advance therapeutic solutions across a range of diseases. Its expertise spans from target identification to clinical development, with collaborations focused on innovative approaches in areas like oncology, immunology, and metabolic diseases. The company’s partnership with Bristol Myers Squibb (BMS) in neuroscience has yielded substantial progress and triggered a $20 million research payment to Evotec (NASDAQ:EVO). This long-standing collaboration, which was initiated in 2016 and is extended through 2031, develops disease-modifying treatments for neurodegenerative diseases. The partnership has already resulted in the in-licensing of EVT8683 (BMS-986419) by BMS. Evotec’s (NASDAQ:EVO) LAB eN² drug discovery accelerator, in partnership with Novo Nordisk, has selected its first three projects and aims to translate academic research into novel therapeutics for cardiometabolic conditions. This program has expanded to include 5 new academic institutions. Furthermore, Evotec (NASDAQ:EVO) has secured a $4.5 million grant from the Korean government, alongside Yonsei University and Zymedi, to develop novel antibody-based treatments for lung diseases. Overall, EVO ranks 12th on our list of best German stocks to buy according to hedge funds. While we acknowledge the growth potential of EVO, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than EVO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. View Comments |
||
| 04.03.25 06:45:00 | Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb | |
| Ongoing strategic partnership advances joint pipeline in neurodegeneration research Evotec receives a $20 million payment to further progress research HAMBURG, DE / ACCESS Newswire / March 4, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN:DE0005664809; NASDAQ:EVO) today announced another major accomplishment in its long-standing neuroscience collaboration with Bristol Myers Squibb (NYSE: BMY). The latest scientific achievement in the partnership has triggered a research payment of US$20 m to Evotec, enabling further development of a promising pre-clinical programme in neurodegeneration. Since the initiation of their strategic neuroscience collaboration in December 2016, Evotec and Bristol Myers Squibb have been working together to identify disease-modifying treatments for a broad range of neurodegenerative diseases. While currently approved therapies primarily focus on symptom management, this partnership aims to develop transformative treatments that can slow or halt disease progression - addressing a significant unmet medical need. The collaboration has already yielded strong results, including the in-licensing of EVT8683 (now BMS-986419) by Bristol Myers Squibb in September 2021. In March 2023, the companies reaffirmed their commitment by extending and expanding the collaboration for an additional eight years. Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "This latest achievement further underscores the strength of our collaboration with Bristol Myers Squibb and the impact it has for jointly building a strong pipeline in neurological diseases. Our continued success highlights the unique commitment and reinforces our shared mission to deliver truly innovative treatment options for patients suffering from neurodegenerative diseases. With another high-potential program advancing towards clinical development, we are taking yet another important step in our pursuit of breakthrough therapies." About Evotec SE Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn. Story Continues Forward-looking statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. For further information, please contact: Investor Relations Volker Braun EVP Head of Global Investor Relations & ESG Volker.Braun@evotec.com Media Susanne Kreuter VP Head of Strategic Marketing Susanne.Kreuter@evotec.com SOURCE: Evotec SE View the original press release on ACCESS Newswire View Comments |
||
| 26.02.25 07:00:00 | Evotec Announces Change in Management Board |  |
| Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025 Paul Hitchin appointed to succeed as Chief Financial Officer effective 1 March 2025 HAMBURG, GERMANY / ACCESS Newswire / February 26, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its Chief Financial Officer, Laetitia Rouxel, will step down from her role of Chief Financial Officer effective 28 February 2025 and leave the Company effective 31 March 2025 to pursue other opportunities. Laetitia Rouxel joined Evotec in April 2023 as Chief Financial Officer and member of the Management Board of Evotec. Paul Hitchin has been appointed by the Supervisory Board to succeed Laetitia Rouxel, effective 1 March 2025. Paul has over 20 years of experience in various finance leadership positions, most recently as CFO of Mediq where he was responsible for all financial activities of the company including responsibility for IT & M&A. During Paul's time with Mediq he led programs to significantly grow the business whilst driving a transformation agenda to improve profitability and efficiency. Prior to Mediq, Paul spent 13 years with General Electric in a number of CFO positions including 5 years with GE Healthcare. Paul holds a BA in Economics and French from Keele University and is a Chartered Management Accountant with CIMA. Paul's extensive financial expertise and broad experience with transformation will be instrumental for Evotec as we accelerate our new strategic journey towards profitable and sustainable growth. Prof. Dr Iris Löw-Friedrich, Chairwoman of the Supervisory Board of Evotec, said: "On behalf of Evotec's Supervisory Board, I would like to sincerely thank Laetitia for her many contributions and her dedication to Evotec over the past two years. Laetitia's leadership during the recent challenging times has been crucial and we are very grateful for her commitment. We wish her all the very best for her future endeavours. At the same time, we are pleased to welcome Paul Hitchin as Evotec's new Chief Financial Officer. His deep financial expertise and his extensive experience with transformation will be essential for Evotec at this important juncture on the path to profitable and sustainable growth." Laetitia Rouxel, Chief Financial Officer of Evotec SE commented: "I am grateful to have worked alongside such talented Evotec colleagues. I want to extend my heartfelt gratitude to everyone for their dedication, and especially to the teams I had the privilege of leading. I firmly believe that with bold, courageous leadership and collective determination, Evotec will achieve the success it deserves." Story Continues Paul Hitchin, designated Chief Financial Officer of Evotec SE, commented: "I am very excited to join the talented and passionate Evotec team at this pivotal time of its journey. I look forward to building on the work the team has done so far to accelerate the path to sustainable and profitable growth for Evotec." Dr Christian Wojczewski, Chief Executive Officer of Evotec, added: "On behalf of the Management Board, I would like to thank Laetitia for her leadership, her collaborative and constructive team spirit and her positive impact on achieving our 2024 financial goals, including a significant improvement of liquidity in Q4. It has been a pleasure to work with her these past eight months and I wish her all the very best. I am very happy to welcome Paul to the team and look forward to shaping the next chapter of Evotec's journey together." About Evotec SE Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 120 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally close to 5,000 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.comand follow us on X/Twitter @Evotecand LinkedIn. Forward-looking statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. For further information, please contact: Investor Relations Volker Braun EVP Head of Global Investor Relations & ESG Volker.Braun@evotec.com SOURCE: Evotec SE View the original press release on ACCESS Newswire View Comments |
||
| 22.01.25 07:00:00 | Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases | |
| Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and Energy Funding supports a novel collaboration to develop first-in-class therapeutic antibodies to treat asthma and idiopathic pulmonary fibrosis HAMBURG, GERMANY / ACCESS Newswire / January 22, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat lung diseases, including asthma and idiopathic pulmonary fibrosis (IPF). The project will focus on the preclinical development of novel anti-inflammatory and anti-fibrotic antibodies directed against tRNA synthetases, an emerging therapeutic target class to treat diseases with a high unmet medical need. "We are excited to work together with Prof. Sunghoon Kim and our colleagues at Zymedi and Yonsei University to cooperatively advance a particularly promising approach to develop novel antibody-based treatments for asthma and IPF," said Dr Thomas Hanke, EVP & Head of Academic Partnerships at Evotec. "The synergies between the three parties supported by the KIAT grant showcase how international collaborations can help accelerate the development of novel therapies for diseases with a high unmet medical need: Dr. Kim's laboratory at Yonsei University has been recognized as a global leader in the field of tRNA synthetases by uncovering their diverse regulatory activities for body homeostasis. Zymedi is an aspiring Korean company translating the pathologic association of tRNA synthetases to new medicine. Evotec will bring to bear its world-class antibody development, engineering and manufacturing technologies together with its integrated preclinical R&D platforms for drug discovery and development of fibrosis and lung diseases. We are grateful to the Korean government and honored to be part of this outstanding consortium" "The previously untapped biology of tRNA synthetases provides a versatile route for new drug development. I am very excited to launch the project with Evotec to develop novel therapeutic antibodies targeting a disease-causing activities by these enzymes" said Sunghoon Kim, Professor and Director, Institute of Artificial Intelligence and Biomedical Research at Yonsei University. Story Continues The project aims to advance first-in-class antibodies targeting a novel mechanism-of-action in the area of tRNA synthetase biology to treat IPF and non-type 2 asthma. Both disease entities are characterized by a high need to develop novel therapies that will improve future standard-of-care. About Yonsei University Yonsei University, founded in 1885 in Seoul, South Korea, is a prestigious private institution renowned for academic excellence. Ranking #56 in the QS World University Rankings 2025, the university serves approximately 38,725 students across 14 colleges and 15 graduate schools, offering diverse programs in humanities, sciences, engineering, and medicine. Located primarily in Sinchon, Seoul, Yonsei's mission focuses on educating global leaders committed to humanity's progress. The university distinguishes itself through extensive research capabilities, 153 research centers, and a strong international perspective. With a rich academic heritage, Yonsei has produced notable alumni including a Nobel laureate and an Academy Award winner. Embodying values of "truth and freedom", the institution continues to be a leading educational platform preparing students to become innovative global professionals. For additional information please go to www.yonsei.ac.kr . About Zymedi Zymedi is a clinical stage biopharmaceutical company pioneering novel biology of aminoacyl-tRNA synthetases (ARSs) as innovative therapeutic solutions. While traditionally known for their role in protein synthesis, ARSs also play crucial roles in the body's homeostasis-an overlooked function with profound implications for human diseases. Since 2019, Zymedi has focused on harnessing the untapped potential of ARSs, developing first-in-class therapies to address critical unmet medical needs. The company's proprietary drug discovery platform drives its innovation, enabling a robust pipeline of therapies grounded in deep ARS biology. A current key focus disease area includes immune and fibrotic diseases and cancer.Zymedi is currently collaborating with US National Heart, Lung and Blood Institute for clinical studies of ZMA001, a therapeutic antibody for pulmonary arterial hypertension. The company is located in Incheon, Korea and venture-backed. For additional information, please visit www.zymedi.com and follow us on Instagram @zymedi_official and LinkedIn . About Evotec SE Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn . Forward-looking statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. For further information, please contact: Investor Relations Volker Braun EVP Head of Global Investor Relations & ESG Volker.Braun@evotec.com Media Susanne Kreuter VP Head of Strategic Marketing Susanne.Kreuter@evotec.com SOURCE: Evotec SE View the original press release on ACCESS Newswire View Comments |
||
